$16.45
Insights on Certara Inc
Revenue is up for the last 2 quarters, 85.57M → 88.01M (in $), with an average increase of 2.8% per quarter
Netprofit is up for the last 2 quarters, -48.96M → -12.45M (in $), with an average increase of 293.1% per quarter
In the last 1 year, Healthequity Inc has given 49.4% return, outperforming this stock by 79.7%
In the last 3 years, Healthequity Inc has given 8.6% return, outperforming this stock by 54.8%
0.79%
Downside
Day's Volatility :2.53%
Upside
1.76%
28.21%
Downside
52 Weeks Volatility :52.19%
Upside
33.4%
Period | Certara Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 3.91% | 2.0% | 0.0% |
6 Months | 24.39% | 11.7% | 0.0% |
1 Year | -31.24% | 5.8% | 1.3% |
3 Years | -48.59% | 14.2% | -22.1% |
Market Capitalization | 2.6B |
Book Value | $6.55 |
Earnings Per Share (EPS) | -0.35 |
Wall Street Target Price | 19.72 |
Profit Margin | -15.62% |
Operating Margin TTM | -13.56% |
Return On Assets TTM | 0.56% |
Return On Equity TTM | -5.21% |
Revenue TTM | 354.3M |
Revenue Per Share TTM | 2.23 |
Quarterly Revenue Growth YOY | 1.6% |
Gross Profit TTM | 203.1M |
EBITDA | 70.1M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | -0.14 |
EPS Estimate Current Year | 0.43 |
EPS Estimate Next Year | 0.52 |
EPS Estimate Current Quarter | 0.11 |
EPS Estimate Next Quarter | 0.11 |
What analysts predicted
Upside of 19.88%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 163.7M | - |
Net Income | -33.3M | - |
Net Profit Margin | -20.31% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 208.5M | ↑ 27.36% |
Net Income | -8.9M | ↓ 73.16% |
Net Profit Margin | -4.28% | ↑ 16.03% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 243.5M | ↑ 16.79% |
Net Income | -49.4M | ↑ 453.41% |
Net Profit Margin | -20.28% | ↓ 16.0% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 286.1M | ↑ 17.48% |
Net Income | -13.3M | ↓ 73.14% |
Net Profit Margin | -4.64% | ↑ 15.64% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 335.6M | ↑ 17.32% |
Net Income | 14.7M | ↓ 211.04% |
Net Profit Margin | 4.39% | ↑ 9.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 354.3M | ↑ 5.57% |
Net Income | -55.4M | ↓ 475.79% |
Net Profit Margin | -15.62% | ↓ 20.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 84.7M | ↑ 2.34% |
Net Income | 3.9M | ↓ 768.25% |
Net Profit Margin | 4.65% | ↑ 5.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 86.6M | ↑ 2.28% |
Net Income | 9.2M | ↑ 133.08% |
Net Profit Margin | 10.59% | ↑ 5.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 90.3M | ↑ 4.23% |
Net Income | 1.4M | ↓ 85.2% |
Net Profit Margin | 1.5% | ↓ 9.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 90.5M | ↑ 0.17% |
Net Income | 4.7M | ↑ 246.54% |
Net Profit Margin | 5.2% | ↑ 3.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 85.6M | ↓ 5.39% |
Net Income | -49.0M | ↓ 1140.48% |
Net Profit Margin | -57.22% | ↓ 62.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 88.0M | ↑ 2.84% |
Net Income | -12.5M | ↓ 74.56% |
Net Profit Margin | -14.15% | ↑ 43.07% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | - |
Total Liabilities | 558.7M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 1.37% |
Total Liabilities | 545.0M | ↓ 2.45% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 22.4% |
Total Liabilities | 447.3M | ↓ 17.94% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 19.09% |
Total Liabilities | 469.9M | ↑ 5.06% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 4.05% |
Total Liabilities | 493.3M | ↑ 4.98% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↓ 0.62% |
Total Liabilities | 516.3M | ↑ 4.67% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 0.46% |
Total Liabilities | 454.3M | ↑ 0.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 4.26% |
Total Liabilities | 493.3M | ↑ 8.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↓ 0.39% |
Total Liabilities | 481.7M | ↓ 2.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 0.35% |
Total Liabilities | 475.0M | ↓ 1.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 2.89% |
Total Liabilities | 475.1M | ↑ 0.01% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 2.38% |
Total Liabilities | 516.3M | ↑ 8.68% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.6M | - |
Investing Cash Flow | -73.9M | - |
Financing Cash Flow | 57.3M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.0M | ↑ 228.03% |
Investing Cash Flow | -9.5M | ↓ 87.12% |
Financing Cash Flow | -8.5M | ↓ 114.82% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 44.8M | ↑ 17.84% |
Investing Cash Flow | -8.6M | ↓ 9.51% |
Financing Cash Flow | 208.2M | ↓ 2552.75% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 60.4M | ↑ 34.76% |
Investing Cash Flow | -269.9M | ↑ 3034.25% |
Financing Cash Flow | 123.4M | ↓ 40.74% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 92.5M | ↑ 53.25% |
Investing Cash Flow | -27.8M | ↓ 89.69% |
Financing Cash Flow | -7.4M | ↓ 105.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 24.0M | ↑ 3.17% |
Investing Cash Flow | -3.3M | ↑ 2.66% |
Financing Cash Flow | -1.3M | ↓ 61.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.5M | ↑ 47.88% |
Investing Cash Flow | -12.6M | ↑ 279.03% |
Financing Cash Flow | -968.0K | ↓ 27.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.0M | ↓ 71.94% |
Investing Cash Flow | -2.7M | ↓ 78.32% |
Financing Cash Flow | -850.0K | ↓ 12.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 18.1M | ↑ 81.36% |
Investing Cash Flow | -11.7M | ↑ 329.55% |
Financing Cash Flow | -6.4M | ↑ 655.29% |
Sell
Neutral
Buy
Certara Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Certara Inc | -1.12% | 24.39% | -31.24% | -48.59% | -56.07% |
Solventum Corp | -8.1% | -8.1% | -8.1% | -8.1% | -8.1% |
Veeva Systems Inc. | -12.34% | 1.98% | 7.91% | -29.07% | 47.16% |
Ge Healthcare Technologies Inc. | -2.31% | 33.35% | -1.77% | 42.57% | 42.57% |
Healthequity Inc | 0.62% | 10.75% | 49.37% | 4.64% | 14.82% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Certara Inc | 100.92 | NA | NA | 0.43 | -0.05 | 0.01 | NA | 6.55 |
Solventum Corp | NA | NA | NA | 0.0 | 0.12 | 0.08 | NA | NA |
Veeva Systems Inc. | 61.82 | 61.82 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 28.4 | 28.4 | 20.11 | 4.3 | 0.19 | 0.06 | 0.0 | 15.67 |
Healthequity Inc | 126.86 | 126.86 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Certara Inc | Buy | $2.6B | -56.07% | 100.92 | -15.62% |
Solventum Corp | NA | $11.7B | -8.1% | NA | 16.42% |
Veeva Systems Inc. | Buy | $32.1B | 47.16% | 61.82 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $39.4B | 42.57% | 28.4 | 8.02% |
Healthequity Inc | Buy | $7.0B | 14.82% | 126.86 | 5.57% |
BlackRock Inc
Vanguard Group Inc
Mubadala Investment Company PJSC
Baillie Gifford & Co Limited.
William Blair Investment Management, LLC
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.
Organization | Certara Inc |
Employees | 1338 |
CEO | Dr. William F. Feehery Ph.D. |
Industry | Healthcare |
Amn Healthcare Services Inc.
$16.45
-1.67%
Tenet Healthcare Corp.
$16.45
-1.67%
Surgery Partners Inc
$16.45
-1.67%
Penumbra Inc
$16.45
-1.67%
Corcept Therapeutics Inc
$16.45
-1.67%
Vaxcyte Inc
$16.45
-1.67%
Option Care Health Inc
$16.45
-1.67%
Springworks Therapeutics Inc
$16.45
-1.67%
Acadia Pharmaceuticals Inc.
$16.45
-1.67%